Diabetic kidney disease: what we know so far - literature review
DOI:
https://doi.org/10.12775/QS.2024.18.54036Keywords
diabetes mellitus, diabetic kidney disease, oxidative stress, SGLT-2 inhibitors, hyperglycemiaAbstract
Diabetic Kidney Disease (DKD) is a major complication of diabetes mellitus, affecting approximately 40% of diabetic patients and representing the leading cause of chronic kidney disease and end-stage renal disease (ESRD). This review delves into the pathogenesis, diagnosis, and therapeutic advancements in DKD. Key pathological mechanisms include hyperglycemia, oxidative stress, and inflammation. Modern treatments, such as SGLT-2 inhibitors and GLP-1 agonists, offer renoprotective benefits by improving endothelial function, reducing inflammation, and mitigating oxidative stress. The review also highlights the importance of timely initiation and optimization of therapies to slow DKD progression and explores new avenues such as epigenetic therapies and autophagy enhancement. Further research is needed to fully understand the long-term benefits and optimal use of these treatments in DKD management.
References
Lin YC, Chang YH, Yang SY, Wu KD, Chu TS. Update of pathophysiology and management of diabetic kidney disease. J Formos Med Assoc. 2018 Aug;117(8):662-675. doi: 10.1016/j.jfma.2018.02.007. Epub 2018 Mar 2. PMID: 29486908.
Liu Z, Liu J, Wang W, An X, Luo L, Yu D, Sun W. Epigenetic modification in diabetic kidney disease. Front Endocrinol (Lausanne). 2023 Jun 30;14:1133970. doi: 10.3389/fendo.2023.1133970. PMID: 37455912; PMCID: PMC10348754.
Ahmad AA, Draves SO, Rosca M. Mitochondria in Diabetic Kidney Disease. Cells. 2021 Oct 29;10(11):2945. doi: 10.3390/cells10112945. PMID: 34831168; PMCID: PMC8616075.
Sugahara M, Pak WLW, Tanaka T, Tang SCW, Nangaku M. Update on diagnosis, pathophysiology, and management of diabetic kidney disease. Nephrology (Carlton). 2021 Jun;26(6):491-500. doi: 10.1111/nep.13860. Epub 2021 Feb 17. PMID: 33550672.
Sindhu D, Sharma GS, Kumbala D. Management of diabetic kidney disease: where do we stand?: A narrative review. Medicine (Baltimore). 2023 Mar 31;102(13):e33366. doi: 10.1097/MD.0000000000033366. PMID: 37000108; PMCID: PMC10063294.
Tuttle KR, Agarwal R, Alpers CE, Bakris GL, Brosius FC, Kolkhof P, Uribarri J. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 2022 Aug;102(2):248-260. doi: 10.1016/j.kint.2022.05.012. Epub 2022 Jun 3. PMID: 35661785.
Hung PH, Hsu YC, Chen TH, Lin CL. Recent Advances in Diabetic Kidney Diseases: From Kidney Injury to Kidney Fibrosis. Int J Mol Sci. 2021 Nov 1;22(21):11857. doi: 10.3390/ijms222111857. PMID: 34769288; PMCID: PMC8584225.
Wang Y, Jin M, Cheng CK, Li Q. Tubular injury in diabetic kidney disease: molecular mechanisms and potential therapeutic perspectives. Front Endocrinol (Lausanne). 2023 Aug 2;14:1238927. doi: 10.3389/fendo.2023.1238927. PMID: 37600689; PMCID: PMC10433744.
Ma X, Ma J, Leng T, Yuan Z, Hu T, Liu Q, Shen T. Advances in oxidative stress in pathogenesis of diabetic kidney disease and efficacy of TCM intervention. Ren Fail. 2023 Dec;45(1):2146512. doi: 10.1080/0886022X.2022.2146512. PMID: 36762989; PMCID: PMC9930779.
Xu C, Ha X, Yang S, Tian X, Jiang H. Advances in understanding and treating diabetic kidney disease: focus on tubulointerstitial inflammation mechanisms. Front Endocrinol (Lausanne). 2023 Oct 4;14:1232790. doi: 10.3389/fendo.2023.1232790. PMID: 37859992; PMCID: PMC10583558.
Jung SW, Moon JY. The role of inflammation in diabetic kidney disease. Korean J Intern Med. 2021 Jul;36(4):753-766. doi: 10.3904/kjim.2021.174. Epub 2021 Jul 1. PMID: 34237822; PMCID: PMC8273831.
Watanabe K, Sato E, Mishima E, Miyazaki M, Tanaka T. What's New in the Molecular Mechanisms of Diabetic Kidney Disease: Recent Advances. Int J Mol Sci. 2022 Dec 29;24(1):570. doi: 10.3390/ijms24010570. PMID: 36614011; PMCID: PMC9820354.
Rico-Fontalvo J, Aroca G, Cabrales J, Daza-Arnedo R, Yánez-Rodríguez T, Martínez-Ávila MC, Uparella-Gulfo I, Raad-Sarabia M. Molecular Mechanisms of Diabetic Kidney Disease. Int J Mol Sci. 2022 Aug 4;23(15):8668. doi: 10.3390/ijms23158668. PMID: 35955802; PMCID: PMC9369345.
Lebedeva S, Margaryan A, Smolyarchuk E, Nedorubov A, Materenchuk M, Tonevitsky A, Mutig K. Metabolic effects of vasopressin in pathophysiology of diabetic kidney disease. Front Endocrinol (Lausanne). 2023 Sep 18;14:1176199. doi: 10.3389/fendo.2023.1176199. PMID: 37790608; PMCID: PMC10545091.
Gonzalez CD, Carro Negueruela MP, Nicora Santamarina C, Resnik R, Vaccaro MI. Autophagy Dysregulation in Diabetic Kidney Disease: From Pathophysiology to Pharmacological Interventions. Cells. 2021 Sep 21;10(9):2497. doi: 10.3390/cells10092497. PMID: 34572148; PMCID: PMC8469825.
Lytvyn Y, Bjornstad P, van Raalte DH, Heerspink HL, Cherney DZI. The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications. Endocr Rev. 2020 Apr 1;41(2):202–31. doi: 10.1210/endrev/bnz010. PMID: 31633153; PMCID: PMC7156849.
Winiarska A, Knysak M, Nabrdalik K, Gumprecht J, Stompór T. Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists. Int J Mol Sci. 2021 Oct 6;22(19):10822. doi: 10.3390/ijms221910822. PMID: 34639160; PMCID: PMC8509708.
Lu, YP., Zhang, ZY., Wu, HW. et al. SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease. J Transl Med 20, 420 (2022).
Song J, Li X, Ni J. A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review. Kidney Blood Press Res. 2023;48(1):599-610. doi: 10.1159/000534174. Epub 2023 Sep 16. PMID: 37717569; PMCID: PMC10614480.
Radica Z. Alicic, Joshua J. Neumiller, Emily J. Johnson, Brad Dieter, Katherine R. Tuttle; Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease. Diabetes 1 February 2019; 68 (2): 248–257.
Dai ZC, Chen JX, Zou R, Liang XB, Tang JX, Yao CW. Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease. Front Immunol. 2023 Sep 21;14:1213473. doi: 10.3389/fimmu.2023.1213473. PMID: 37809091; PMCID: PMC10552262.
Gembillo G, Ingrasciotta Y, Crisafulli S, Luxi N, Siligato R, Santoro D, Trifirò G. Kidney Disease in Diabetic Patients: From Pathophysiology to Pharmacological Aspects with a Focus on Therapeutic Inertia. Int J Mol Sci. 2021 May 1;22(9):4824. doi: 10.3390/ijms22094824. PMID: 34062938; PMCID: PMC8124790.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Piotr Kuczyński, Anna Marszałek, Maciej Choiński, Paulina Wasiewicz-Ciach, Marcelina Teresa Marzec, Aleksandra Wydra-Rojek, Aleksandra Łakoma, Weronika Zofia Marzec, Katarzyna Kutyła, Wojciech Jan Mokot

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 146
Number of citations: 0